Literature DB >> 27100618

Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia.

Jill Samis1,2, Paul Lee3, Donald Zimmerman1,2, Robert J Arceci4, Meinolf Suttorp5, Nobuko Hijiya2,3.   

Abstract

Side effects of tyrosine kinase inhibitor (TKI) treatment vary in children and adults with chronic myelogenous leukemia (CML). As children have a much longer life expectancy than adults, TKI therapy may continue for decades and with long-term consequences that differ from adults. Children may develop endocrinopathies related to "off-target" effects of TKIs, such as delayed growth, changes in bone metabolism, thyroid abnormalities, and effects on puberty and fertility. These endocrinopathies present additional challenges for pediatric patients with CML. This review critically evaluates the literature on long-term endocrine side effects of TKIs in the pediatric CML population and provides suggested recommendations.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  CML; TKI; children; endocrine; growth

Mesh：

Substances：

Year:  2016        PMID： 27100618     DOI： 10.1002/pbc.26028

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  16 in total

1.  Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China.

Authors:  Yuli Cai; Chao Liu; Ye Guo; Xiaojuan Chen; Li Zhang; Yumei Chen; Yao Zou; Wenyu Yang; Xiaofan Zhu
Journal:  Int J Hematol       Date:  2021-01-01       Impact factor: 2.490

Review 2.  Tyrosine Kinase Inhibitors and Beyond for Chronic Myeloid Leukemia in Children.

Authors:  Lia N Phillips; Nobuko Hijiya
Journal:  Paediatr Drugs       Date:  2021-04-26       Impact factor: 3.022

3.  Outcome prediction of chronic myeloid leukemia (CML) in children.

Authors:  Wing-Yan Leung; Daniel Ka-Leung Cheuk; Frankie Wai-Tsoi Cheng; Alex Wing-Kwan Leung; Ka-Ho Chiu; Karin Kar-Huen Ho; Chak-Ho Li; Godfrey Chi-Fung Chan
Journal:  Ann Hematol       Date:  2022-06-01       Impact factor: 4.030

Review 4.  Endocrine Late Effects in Childhood Cancer Survivors.

Authors:  Paula Casano-Sancho; Ana Carolina Izurieta-Pacheco
Journal:  Cancers (Basel)       Date:  2022-05-26       Impact factor: 6.575

Review 5.  Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician's perspective.

Authors:  Deepam Pushpam; Sameer Bakhshi
Journal:  Daru       Date:  2020-01-03       Impact factor: 3.117

Review 6.  Chronic Myelogenous Leukemia in Childhood.

Authors:  Stephanie M Smith; Nobuko Hijiya; Kathleen M Sakamoto
Journal:  Curr Oncol Rep       Date:  2021-03-14       Impact factor: 5.075

Review 7.  Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review.

Authors:  Anupama Rambhatla; Michael R Strug; Jessica Garcia De Paredes; Marcos I Cordoba Munoz; Mili Thakur
Journal:  J Assist Reprod Genet       Date:  2021-04-07       Impact factor: 3.357

Review 8.  Factors influencing risk-based care of the childhood cancer survivor in the 21st century.

Authors:  Stephanie B Dixon; Kari L Bjornard; Nicole M Alberts; Gregory T Armstrong; Tara M Brinkman; Wassim Chemaitilly; Matthew J Ehrhardt; Israel Fernandez-Pineda; Lisa M Force; Todd M Gibson; Daniel M Green; Carrie R Howell; Sue C Kaste; Anne C Kirchhoff; James L Klosky; Kevin R Krull; John T Lucas; Daniel A Mulrooney; Kirsten K Ness; Carmen L Wilson; Yutaka Yasui; Leslie L Robison; Melissa M Hudson
Journal:  CA Cancer J Clin       Date:  2018-01-29       Impact factor: 508.702

9.  A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety.

Authors:  Nobuko Hijiya; Alexey Maschan; Carmelo Rizzari; Hiroyuki Shimada; Carlo Dufour; Hiroaki Goto; Hyoung Jin Kang; Terri Guinipero; Zeynep Karakas; Francisco Bautista; Stéphane Ducassou; Keon Hee Yoo; Christian Michel Zwaan; Frédéric Millot; Briana Patterson; Jill Samis; Paola Aimone; Alex Allepuz; Ksenia Titorenko; Darintr Sosothikul
Journal:  Blood Adv       Date:  2021-07-27

Review 10.  Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis.

Authors:  Monika Sparber-Sauer; Daniel Orbach; Fariba Navid; Simone Hettmer; Stephen Skapek; Nadège Corradini; Michela Casanova; Aaron Weiss; Matthias Schwab; Andrea Ferrari
Journal:  Br J Cancer       Date:  2021-03-15       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.